Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
Continue Reading
-
Noosa News8 hours agoHow Lily Steele-Park took her rapist to court and won
-
General21 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business12 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General23 hours agoFears for next anti-Semitic firebombing on home soil